Status:
UNKNOWN
Efficacy of Defurocumarinized Bergamot in the Treatment of Agitation in Severe Dementia Patients.
Lead Sponsor:
S.Anna Rehabilitation Institute
Conditions:
Severe Dementia
Stroke
Eligibility:
All Genders
65-80 years
Phase:
NA
Brief Summary
This study evaluates the efficacy of defurocumarinized bergamot in the treatment of agitation in severe dementia patients. Bergamot essential oil (BEO), able to modulate the endogenous, peripheral and...
Detailed Description
According to the World Alzheimer's Report 2018, 50 million people worldwide suffer from dementia and it is estimated that this number will triple by 2050. Very often people with dementia suffer from ...
Eligibility Criteria
Inclusion
- Diagnosis of severe dementia by MMSE score\<12;
- Signature of informed consent by a family member/caregiver/support administrator;
- The use of authorised and concomitant therapies for the treatment of agitation is permitted.
Exclusion
- Positive remote case history for pre-existing neurological or psychiatric disabling conditions
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT04321889
Start Date
April 1 2020
End Date
June 30 2021
Last Update
March 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.